Newsroom

THE GAMALEYA CENTER STATEMENT

“A recently published small study addresses Sputnik vaccine’s efficacy against Omicron variant deliberately using serum samples that are not representative. For example, this study used Sputnik samples with a lower virus neutralization ability against SARS-COV-2 than AstraZeneca’s vaccine while a much larger study in Argentina based on representative serum samples demonstrated 1.8 times higher virus neutralizing titers against SARS-COV-2 for Sputnik, which is explained by its heterologous boosting advantage. Therefore, conclusions about Sputnik efficacy against Omicron based on wrong serum samples, cannot be made. Within the next 7 days the Gamaleya Center will publish its own positive data based on representative serum samples on Omicron neutralization ability for both Sputnik V vaccine and one-shot Sputnik Light as a booster.

In other studies with representative samples Sputnik also induced a stronger and long lasting T-cell immunity, showing an 80% efficacy against Delta on months 6-8 compared with efficacy of less than 29% demonstrated by mRNA vaccines after 6 months.”

Message has been successfully sent!

Thank you!
You have been subscribed